Home/Stocks/Consumer Cyclicals

Frasers Group PLC

FRAS.L·Consumer Cyclicals·Market Cap £3.7b
Rank #264 of 280
Quantitative Model · 280 Stocks Analysed
£8.38
+23.67% YTD
52W: £5.98 - £8.60

Factor Analysis Summary

Editorial assessment generated from Frasers Group PLC's live factor scores and sector positioning.

Based on Strategyland's proprietary 7-factor analysis, Frasers Group PLC (FRAS.L) currently holds an overall rank of #264 out of 280 FTSE 100 constituents, reflecting its weighted composite score across liquidity, valuation, profitability, solvency, asset efficiency, market trading, and technical dimensions.

Key strengths include asset efficiency, where it demonstrates highly efficient capital deployment, converting assets into revenue and returns effectively, and technical (RSI 68.8), where it demonstrates generally favourable technical indicators with price holding above key moving averages.

Areas requiring attention include profitability (ROE 15.6%, net margin 6.6%), where compressed margins and weak returns on equity weigh on the earnings profile, as well as market trading, where low relative volume or adverse volatility patterns may deter momentum-oriented investors.

Within the Consumer Cyclicals sector, Frasers Group PLC sits at composite rank #264, trailing the Consumer Cyclicals peer average (rank 44). It ranks behind all 6 tracked Consumer Cyclicals peers in our model.

The composite profile is weighed down by 5 below-average factor scores, with profitability (rank 233/280) representing the most significant drag on its #264 overall standing.

Strongest Factors

  • Asset Efficiency — Rank 56/280 (top quartile)
  • Technical — Rank 82/280 (above average)
  • Valuation — Rank 190/280 (below average)

Weakest Factors

  • Profitability — Rank 233/280 (below average)
  • Market Trading — Rank 228/280 (below average)

Score Analysis

Frasers Group PLC is ranked #264 out of 280 UK stocks. Lower factor scores indicate better performance in that category.

Factor Breakdown

171/280
Average Score
Liquidity
Weak210/280
Valuation
Weak190/280
Profitability
Weak233/280
Solvency
Weak201/280
Asset Efficiency
Excellent56/280
Mkt Trading
Weak228/280
Technical
Good82/280

1. Liquidity

Score: 210/280

How liquid is FRAS and can it meet its short-term obligations?

1/6
liquidity criteria met
✓
Quick Ratio0.95x
Range: 0.7 - 1.2Rank 76/280
✗
Current Ratio1.80x
Range: 1.2 - 1.8Rank 89/280
✗
TTM Operating Cash Flow0.35x
Range: 0.8 - 1.2Rank 152/280
–
Liquidity Coverage RatioN/A
Range: N/A
✗
Intangible Asset Ratio0.00x
Range: 3 - 15Rank 166/280
✗
Cash-to-Debt Ratio0.15x
Range: 0.3 - 0.8Rank 176/280

Key Liquidity Metrics

Quick Ratio
0.95x
Sector: 0.7 - 1.2
Current Ratio
1.80x
Sector: 1.2 - 1.8

Overall Liquidity Rank

Rank within universe#210/280
Best (1)Worst (280)

2. Valuation

Score: 190/280

Is FRAS undervalued compared to its peers and fair value metrics?

1/7
valuation criteria met
✗
FY27e P/E7.8x
Range: 12x - 30xRank 27/280
✗
FY26e P/E8.1x
Range: 12x - 30xRank 25/280
–
FY27e Net Div Yld (%)N/A
Range: 1.0 - 4.0Rank 207/280
–
Div Payout RatioN/A
Range: 25 - 50Rank 50/280
✓
Current EV/EBITDA7.9x
Range: 7.0x - 11.0xRank 135/280
✗
Current P/TBV1.27x
Range: 1.5x - 4.5xRank 101/280
✗
Current P/B1.22x
Range: 1.5x - 4.5xRank 119/280

Key Valuation Metrics

TTM P/E
Price-to-Earnings
10.6x
FY26e P/E
Forward estimate
8.1x
FY27e P/E
Forward estimate
7.8x
Current P/B
Price-to-Book
1.22x
Current P/TBV
Tangible Book Value
1.27x
Current EV/EBITDA
Enterprise Value
7.9x
FY26e EV/EBITDA
Forward estimate
6.5x
FY27e EV/EBITDA
Forward estimate
5.7x

Dividend

FRAS does not currently pay a significant dividend.

—
No dividend data available for this stock.

3. Profitability

Score: 233/280

How profitable is FRAS relative to its peers?

1/7
profitability criteria met
✓
TTM Profit Margin6.6%
Range: 3 - 8Rank 182/280
✗
T12 FCF Margin-0.4%
Range: 3 - 10Rank 233/280
✗
FY27e RoE12.8%
Range: 5 - 12Rank 137/280
✗
FY26 EPS Growth22.5%
Range: 0 - 5Rank 54/280
✗
FY27e EPS Growth27.0%
Range: 5 - 12Rank 81/280
–
NIMN/A
Range: N/A
–
Expense RatioN/A
Range: 85 - 92
TTM Profit Margin
6.6%
Current RoCE
15.6%
FY27e RoE
12.8%
T12 FCF Margin
-0.4%

EPS Growth

4. Solvency

Score: 201/280

How strong is FRAS's balance sheet and financial position?

2/6
solvency criteria met
✓
Debt/Eqt1.03x
Range: 0.5x - 1.2xRank 200/280
–
Interest Coverage RatioRank 227
Range: 3x - 8xRank 227/280
✓
Net Leverage Ratio1.69x
Range: 1.5x - 3.5xRank 106/280
–
Altman Z-Score (Manufacturing)3.81
Range: <1.10 - >2.60Rank 148/280
–
Z-Score (Non Manufacturing)Rank 165
Range: <1.10 - >2.60Rank 165/280
–
CapAdeq Ratio Tier1N/A
Range: N/A

Key Solvency Metrics

Debt/Eqt
1.03x
Net Leverage Ratio
1.69x
Interest Coverage
Rank 227
T12 FCF Margin
-0.4%

Altman Z-Score

3.81
Safe Zone
01.812.995+

5. Asset Efficiency

Score: 56/280

How efficiently does FRAS deploy its assets and intellectual capital?

0/5
asset efficiency criteria met
–
Efficiency RatioN/A
Range: N/A
✗
TTM Asset Turnover Ratio0.90x
Range: 1.0x - 2.5xRank 61/280
✗
TTM CAPEX/Sales12.5%
Range: 3 - 8Rank 47/280
✗
Working Capital Turnover4.52x
Range: 5x - 12xRank 91/280
–
R&D/Sales FY27eN/A
Range: 0.5 - 3.0

Overall Asset Efficiency Rank

Rank within sector peers#56/280
Best (1)Worst (280)

6. Market Trading

Score: 228/280

How liquid and actively traded is FRAS?

2/2
market trading criteria met
✓
Intraday Sentiment (%)34.0%
Range: 30 - 70Rank 170/280
–
10D-Avg v/s 3M-Avg Vol55%
Range: N/ARank 100/280
✓
Avg Directional Index 30D12.4
Range: 012 - 45Rank 263/280
–
Parabolic SAR810.46
Range: N/ARank 110/280
–
Stock Rating RankN/A
Range: N/A
Market Cap
£3,729,522,139
Enterprise Value
£5,902,495,953

Trading Volume

7. Technical

Score: 82/280

What do the technical indicators say about FRAS?

0/5
technical criteria met
–
CMP v/s 52-WH-2.5%
£8.60£5.98
-2.5%CMP: £8.38
Range: N/ARank 26/280
–
CMP v/s 52-WL40.2%
£8.60£5.98
+40.2%CMP: £8.38
Range: N/ARank 197/280
–
RSI 14D68.8
068.8 - Bullish100
Range: N/ARank 50/280
–
MA50 - MA200Bullish
£7.29+0.78£8.08
Range: N/ARank 60/280
–
MACD Rank4.85
Golden Cross
MACD: 4.85
Range: N/ARank 100/280

RSI (14 Day)

68.8
Bullish
0 (Oversold)50100 (Overbought)

Moving Averages

50 SMA£8.08
200 SMA£7.29
SignalGolden Cross (Bullish)
MACD4.85

Risk Metrics

Beta
N/A
3-Yr Std Dev
0.3%
5-Yr Std Dev
0.3%

Peer Comparison

How does FRAS compare to other Consumer Cyclicals stocks?

Overall Rank Comparison

Factor Score Comparison

StockRankLiquidityValuationProfitabilitySolvencyMkt TradingTechnical
FRAS#26421019023320122882
GAW.L#109267933618240
NXT.L#224026194105233
FOUR.L#31135202184248212
GFTU_u.L#564914521812515311
MOONM.L#70144178158161135116
CPG.L#72156203150129266215
Sponsored
Healthcare Discovery Monitor
Live
Healthcare Discovery Monitor
Healthcare Discovery Monitorby StrategyLand

Catch Healthcare Events Before the Market Moves

SEC filings, FDA approvals, clinical trials, and regulatory events - scored for significance across 4 global markets.

10+
Sources
4
Markets
12h
Cycle
50+
Keywords
USUKCNEU
Launch Monitor

Methodology Note

The analysis presented for Frasers Group PLC is produced using Strategyland's proprietary 7-factor quantitative model, which evaluates each stock across Liquidity, Valuation, Profitability, Solvency, Asset Efficiency, Market Trading, and Technical dimensions. Individual factor scores and the composite rank reflect relative rankings within the FTSE 100 universe — a lower rank number indicates stronger performance in that category.

Underlying financial and market data is sourced from LSEG (London Stock Exchange Group) and processed through our scoring engine. Scores are recalculated as new data becomes available and should be interpreted as a systematic screening output, not a forecast of future share price performance.

This content is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance and factor rankings are not indicative of future results. Please read our Risk Disclaimer before making any investment decisions.

Note: The information provided is not intended as an offer or solicitation for the purchase or sale of any financial instruments but for investor relations purposes only. The aforementioned securities were offered to the public and currently trade on the secondary market at the exchange mentioned above. It is recommended that investors considering investing in any of these notes consult an approved MiFID Financial Advisor prior to investing.